What is Veristat?
Founded in 1994, Veristat operates as a full-service, science-focused clinical research organization (CRO). The company occupies a critical niche in the healthcare ecosystem, providing essential support for complex clinical trials and navigating the intricate regulatory submission processes required by pharmaceutical, biotechnology, and medical device manufacturers. By leveraging deep scientific expertise, Veristat enables its clients to accelerate the development of life-saving therapies and medical innovations. Its market position is defined by a long-standing track record of delivering high-quality data and regulatory strategy, which remains a cornerstone of its value proposition in an increasingly rigorous global health environment.
How much funding has Veristat raised?
Veristat has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Veristat
PPP
Public-Private Partnership
What's next for Veristat?
Looking ahead, the infusion of capital positions Veristat to further expand its service offerings and technological integration within the clinical development lifecycle. As the firm transitions into its next phase of growth, the focus will likely shift toward enhancing its digital health capabilities and expanding its footprint in specialized therapeutic areas. By maintaining a strategic emphasis on regulatory excellence and operational efficiency, Veristat is well-equipped to navigate the evolving demands of the life sciences industry. This financial backing serves as a catalyst for sustained innovation, ensuring the company remains a preferred partner for organizations seeking to bring complex medical products to market with speed and precision.
See full Veristat company page
